• Type:
  • Category:

BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO

Share

BRAIN Biotech AG FY 2021/22: Key Takeaways

Revenue Growth in BRAIN Biotech AG

BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022/23.

 

BioIndustrial and BioScience Segment Performance

The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by €2.4 million to €10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.

 

Profitability and Investments

Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable.

 

Quarterly Highlights and Collaborations

Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.

 

CFO Insights into Fiscal Year Prospects

Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs.

Chapters

  • Brain at a Glance
  • Group Structure
  • Highlights FY21/22
  • Lowlights FY21/22
  • Akibion Genomics
  • Brain Incubator
  • Financial Highlights FY21/22
  • Cash & Cash Flow
  • Long-Term Revenue Growth Trajectory
  • Adjusted Ebitda
  • Revenue by Region
  • General Risk Factors
  • Targets
  • Share Ownership
  • Financial Calendar

Resources

Host

michaelschneiders - BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO -%sitename%

Michael Schneiders
CFO | BRAIN Biotech AG​

picofme 1 1 - BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO -%sitename%

Martina Schuster
Investor Relations | BRAIN Biotech AG​

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Reviews for BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO
There are currently no reviews for BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

 

Scroll to top